Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026)
Fulgent Genetics (FLGT) posted Cash from Financing Activities of -$24.2 million for Q2 2026, up 45.97% sequentially from -$44.8 million in Q1 2026, and down 818.31% YoY from $3.4 million in Q2 2025.
Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Fulgent Genetics has reported Cash from Financing Activities for 11 years, with the latest figure at -$24.2 million in Q2 2026.
- Quarterly Cash from Financing Activities fell 818.31% year-over-year to -$24.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$70.0 million (down 376.31% YoY) and the FY2025 annual result came in at -$14.8 million, down 205.12% from the prior year.
- Cash from Financing Activities rose to -$24.2 million in Q2 2026 per FLGT's latest filing, from -$44.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at -$327000.0 in Q4 2024 and troughed at -$44.8 million in Q1 2026.
- A 5-year average of -$11.9 million and a median of -$3.6 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 1086.42% in 2022, then jumped 98.74% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$29.6 million in 2022, then rose by 12.31% to -$26.0 million in 2023, then surged by 98.74% to -$327000.0 in 2024, then slumped by 63.3% to -$534000.0 in 2025, then plunged by 4436.52% to -$24.2 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$24.2 million, -$44.8 million, and -$534000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn | -325.19 Mn |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn | -144.00 Mn |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn | -214.00 Mn |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn | 3.76 Mn |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn | -129.00 Mn |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn | -317.75 Mn |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn | -229.00 Mn |
| 10 | Fulgent Genetics | 515.29 Mn | 258.26 Mn | 25.68 Mn | -24.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.23 Mn |
| Jun 30, 2026 | -24.23 Mn |
| Mar 31, 2026 | -44.83 Mn |
| Mar 31, 2026 | -44.83 Mn |
| Dec 31, 2025 | -534,000.00 |
| Dec 31, 2025 | -534,000.00 |
| Sep 30, 2025 | -445,000.00 |
| Sep 30, 2025 | -445,000.00 |
| Jun 30, 2025 | -2.64 Mn |
| Jun 30, 2025 | -2.64 Mn |
| Mar 31, 2025 | -11.17 Mn |
| Mar 31, 2025 | -11.17 Mn |
| Dec 31, 2024 | -327,000.00 |
| Dec 31, 2024 | -327,000.00 |
| Sep 30, 2024 | -567,000.00 |
| Sep 30, 2024 | -567,000.00 |
| Jun 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.15 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Mar 31, 2024 | -2.81 Mn |